Systemic corticosteroids for the treatment of acute episodes of rhabdomyolysis in lipin‐1‐deficient patients
Journal of Inherited Metabolic Disease · 2023
DOI: 10.1002/jimd.12592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2023. Verfasst von Caroline Tuchmann-Durand und 26 weiteren Autor:innen. Beteiligte Einrichtung: Imagine Institute, Biotherapy Clinical Investigation Center, Biotherapy Department, Necker-Enfants-Malades University Hospital, Assistance Publique-H…. Hauptthemen laut MEDLINE: Rhabdomyolysis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, French Muscular Dystrophy Association, Fondation Maladies Rares.
Abstract (Originalsprache)
Mutations in the LPIN1 gene constitute a major cause of severe rhabdomyolysis (RM). The TLR9 activation prompted us to treat patients with corticosteroids in acute conditions. In patients with LPIN1 mutations, RM and at‐risk situations that can trigger RM have been treated in a uniform manner. Since 2015, these patients have also received intravenous corticosteroids. We retrospectively compared data on hospital stays by corticosteroid‐treated patients vs. patients not treated with corticosteroids. Nineteen patients were hospitalized. The median number of admissions per patient was 21 overall and did not differ when comparing the 10 corticosteroid‐treated patients with the 9 patients not treated with corticosteroids. Four patients in the non‐corticosteroid group died during a RM (mean age at death: 5.6 years). There were no deaths in the corticosteroid group. The two groups did not differ significantly in the number of RM episodes. However, for the six patients who had RM and occasionally been treated with corticosteroids, the median number of RM episodes was significantly lower when intravenous steroids had been administered. The peak plasma creatine kinase level and the area under the curve were or tended to be higher in patients treated with corticosteroids—even after the exclusion of deceased patients or focusing on the period after 2015. The median length of stay (10 days overall) was significantly longer for corticosteroid‐treated patients but was similar after the exclusion of deceased patients. The absence of deaths and the higher severity of RM observed among corticosteroid‐treated patients could suggest that corticotherapy is associated with greater survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Imagine Institute, Biotherapy Clinical Investigation Center, Biotherapy Department, Necker-Enfants-Malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
- Université Paris Cité, Health Environmental Risk Assessment (HERA) Team, CRESS, INSERM, INRAE, Paris, France.
- Faculté de Pharmacie de Paris, Université Paris Cité, Paris, France.
- INSERM U1151, Institut Necker Enfants-Malades (INEM), Paris, France.
- Pediatric Intensive Care Unit, Grenoble Alpes University Hospital, Grenoble, France.
- Reference Center for Inherited Metabolic Diseases, Necker-Enfants-Malades University Hospital, APHP, Imagine Institute, G2M, MetabERN, Paris, France.
ORCID-Profile: Caroline Tuchmann-Durand
Förderung
- Agence Nationale de la Recherche
- French Muscular Dystrophy Association
- Fondation Maladies Rares
Zitieren
APA
Tuchmann-Durand, C., Roda, C., Renard, P., Mortamet, G., Bérat, C. M., Altenburger, L., de Larauz, M. H., Thevenet, E., Cottart, C. H., Moulin, F., Bouchereau, J., Brassier, A., Arnoux, J. B., Schiff, M., Bednarek, N., Lamireau, D., Garros, A., Mention, K., Cano, A., …, & de Lonlay, P. (2023). Systemic corticosteroids for the treatment of acute episodes of rhabdomyolysis in lipin‐1‐deficient patients. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12592
Vancouver
Tuchmann-Durand C, Roda C, Renard P, Mortamet G, Bérat CM, Altenburger L, et al. Systemic corticosteroids for the treatment of acute episodes of rhabdomyolysis in lipin‐1‐deficient patients. Journal of Inherited Metabolic Disease. 2023. doi:10.1002/jimd.12592
BibTeX
@article{TuchmannDurand2023,
author = {Tuchmann-Durand, Caroline and Roda, Célina and Renard, Perrine and Mortamet, Guillaume and Bérat, Claire-Marine and Altenburger, Lucile and de Larauz, Marie Hug and Thevenet, Eloise and Cottart, Charles-Henry and Moulin, Florence and Bouchereau, Juliette and Brassier, Anais and Arnoux, Jean-Baptiste and Schiff, Manuel and Bednarek, Nathalie and Lamireau, Delphine and Garros, Alexa and Mention, Karine and Cano, Aline and Finger, Lionel and Pelosi, Michele and Brochet, Cécile Sergent and Caccavelli, Laure and Raphalen, Jean-Herlé and Renolleau, Sylvain and Oualha, Mehdi and de Lonlay, Pascale},
title = {Systemic corticosteroids for the treatment of acute episodes of rhabdomyolysis in lipin‐1‐deficient patients},
journal = {Journal of Inherited Metabolic Disease},
year = {2023},
doi = {10.1002/jimd.12592}
}
EUVIMED